Combination Study of Antibiotics With Enzalutamide (PROMIZE)

PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).

Trial Details

NCT ID
NCT06126731
Phase
PHASE1 / PHASE2
Sponsor
Institute of Cancer Research, United Kingdom
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Enzalutamide 40mg
  • Amoxicillin 500mg
  • Metronidazole 400mg
  • Vancomycin 125mg
  • Ciprofloxacin 500g
Locations (sample)
  • Bellinzona, Switzerland|46.19278,9.01703
  • Sutton, United Kingdom|51.35,-0.2

Key Eligibility Criteria

  • Histologically or cytologically proven metastatic castration-resistant prostate cancer or adenocarcinoma refractory to conventional treatment, or f…
  • Documented prostate cancer progression as assessed by the investigator with RECIST (v1.1) and PCWG3 criteria with at least one of the following cri…
  • Progression of soft tissue/visceral disease by RECIST (v1.1) and/or,
  • Progression of bone disease by PCWG3 bone scan criteria and/or,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →